NSCLC with malignant pleural effusion
Conditions
Interventions
Treatment Group:NK immune cells combined with chemotherapy
Control group:chemotherapy
Sponsors
Shanghai Sixth People Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. At least one measurable lesion, the diameter of the spiral CT scan was 10mm, and the diameter of the ordinary CT scan was 20 mm. 2. ECOG PS 0 and 1; Aged 18-70 years; 3. The expected survival time is > for three months. 4. Cardiac, hepatic, renal and hematopoietic functions were normal before chemotherapy. 5. Laboratory indicators must meet the following requirements: Blood: WBC > 4.0x10^9/L, neutrophil > 1.50x10^9/L, PLT count > 100x10^9/L, Hb > 95g/L; Liver function: serum bilirubin was 1.5 times lower than the maximum normal value, ALT and AST were 1.5 times lower than the maximum normal value; Renal function: serum electrolyte, urea nitrogen and creatinine were all in the normal range.
Exclusion criteria
Exclusion criteria: 1. Pathological types and clinical stages that did not meet the inclusion criteria; 2. Previous chemotherapy or targeted therapy; 3. Receiving other cancer treatment; 4. Patients with any acute or chronic disease or mental disorder or abnormal laboratory examination may increase the risk of participating in the study or study drug use, or affect the study results, and the researchers have determined that patients are not suitable for the study. 1) Uncontrolled hypertension, unstable angina, history of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmias in the past 12 months, active ischemic mucosal disease; 2) Electrocardiogram indicated ischemic changes or clinically diagnosed heart valve disease; 3) Grade III or above peripheral neuropathy; 4) The active period of a bacterial, fungal, or viral infection; 5) Pregnant or lactating women; 6) Having a history of uncontrollable mental illness; 5. Unable to terminate the use of nsaids; 6. Patients with a history of other active malignancies other than small cell lung cancer before enrollment, except for non-melanoma skin cancer, in-situ cervical cancer and early cured prostate cancer; 7. Patients with allergy constitution and known or suspected allergy to any research drugs; 8. Patients with poor compliance; 9. Brain metastases with clinical symptoms (patients with clinically stable and asymptomatic brain metastases without treatment can be enrolled); 10. Peritoneal or pericardial effusion requiring treatment; 11. Accompanied by II degrees or higher diarrhea; 12. Participating in other clinical trials within the first month before randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of target lesions; | — |
Countries
China
Contacts
Public ContactRen Tao
Shanghai Sixth People Hospital
Outcome results
None listed